ASCO GU 2022 Highlights

CME

Key Studies in Urothelial, Prostate, and Kidney Cancer: CCO Independent Conference Highlights of the 2022 Genitourinary Cancers Symposium

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 18, 2022

Expiration: April 17, 2023

Toni K. Choueiri
Toni K. Choueiri, MD
Daniel P. Petrylak
Daniel P. Petrylak, MD

Activity

Progress
1
Course Completed
Introduction

At the 2022 Genitourinary Cancers Symposium held in San Francisco, California, new clinical trial data were reported for genitourinary (GU) malignancies, including prostate cancer, urothelial cancers, and kidney cancer. In this module, Daniel P. Petrylak, MD, and Toni K. Choueiri, MD, review and discuss the clinical implications of key studies presented at the meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: Once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with genitourinary cancers do you provide care for in a typical month?
Based on data showing significantly improved median overall survival (OS) with darolutamide combined with androgen-deprivation therapy (ADT) and docetaxel that was reported from the ARASENS trial, which of the following patient populations would you consider potential candidates for this regimen if it is approved?
The phase III PROpel trial evaluated the addition of olaparib to first-line treatment with abiraterone in patients with metastatic castration-resistant prostate cancer (CRPC) regardless of homologous recombination repair (HRR) mutation status. According to results from this study, which of the following patient populations had the most benefit in terms of prolonged radiographic progression-free survival (rPFS) with the addition of olaparib to abiraterone compared with placebo plus abiraterone?
The phase I/II EV-103 trial enrolled patients with cisplatin-ineligible muscle-invasive bladder cancer (MIBC) onto cohort H, where they received neoadjuvant enfortumab vedotin before proceeding to surgery. Which of the following best describes the effects of neoadjuvant enfortumab vedotin on the pathologic complete response (pCR) rate and surgery in this analysis?
In cohort 3 of the phase II TROPHY-U-01 trial, patients with metastatic urothelial cancer following progression on platinum-based chemotherapy were treated with sacituzumab govitecan plus pembrolizumab. All of the following findings were reported for patients receiving sacituzumab govitecan plus pembrolizumab EXCEPT which one?